Compugen (NASDAQ:CGEN) Stock Passes Above Two Hundred Day Moving Average – What’s Next?

Shares of Compugen Ltd. (NASDAQ:CGEN) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.59 and traded as high as $2.38. Compugen shares last traded at $2.36, with a volume of 1,059,671 shares.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, October 8th. HC Wainwright started coverage on Compugen in a report on Wednesday, January 7th. They set a “buy” rating and a $4.00 target price for the company. Finally, Wall Street Zen raised Compugen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.00.

Compugen Stock Up 11.8%

The stock has a fifty day moving average price of $1.63 and a two-hundred day moving average price of $1.59. The company has a market cap of $210.61 million, a price-to-earnings ratio of -7.87 and a beta of 2.85.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Compugen had a negative net margin of 400.10% and a negative return on equity of 53.60%. The firm had revenue of $1.89 million for the quarter, compared to the consensus estimate of $1.47 million. Analysts predict that Compugen Ltd. will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Compugen

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC raised its holdings in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after buying an additional 359,785 shares during the last quarter. ARK Investment Management LLC increased its position in Compugen by 20.6% in the 2nd quarter. ARK Investment Management LLC now owns 1,072,776 shares of the biotechnology company’s stock valued at $1,785,000 after acquiring an additional 183,107 shares during the period. R Squared Ltd bought a new position in shares of Compugen during the second quarter valued at $71,000. Raymond James Financial Inc. lifted its holdings in shares of Compugen by 51.0% during the third quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 34,215 shares during the period. Finally, Osaic Holdings Inc. grew its stake in shares of Compugen by 346.0% in the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 34,045 shares during the last quarter. 12.22% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.